193 related articles for article (PubMed ID: 36841745)
1. Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial.
Lee JM; Vallières E; Ding B; Johnson A; Bhagwakar J; Rashidi S; Zhu QC; Gitlitz BJ; Weksler B; Costas K; Altorki N
J Thorac Cardiovasc Surg; 2023 Sep; 166(3):655-666.e7. PubMed ID: 36841745
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
[TBL] [Abstract][Full Text] [Related]
3. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Felip E; Altorki N; Zhou C; Vallières E; Martínez-Martí A; Rittmeyer A; Chella A; Reck M; Goloborodko O; Huang M; Belleli R; McNally V; Srivastava MK; Bennett E; Gitlitz BJ; Wakelee HA
Ann Oncol; 2023 Oct; 34(10):907-919. PubMed ID: 37467930
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).
Kenmotsu H; Sugawara S; Watanabe Y; Saito H; Okada M; Chen-Yoshikawa TF; Ohe Y; Nishio W; Nakagawa S; Nagao H
Cancer Sci; 2022 Dec; 113(12):4327-4338. PubMed ID: 36062851
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
6. Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial.
Matsubara T; Yamaguchi M; Shimokawa M; Okamoto I
Clin Lung Cancer; 2024 May; 25(3):280-283. PubMed ID: 38368174
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract][Full Text] [Related]
8. Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer.
Cho JH; Kim J; Kim K; Shim YM; Kim HK; Choi YS
World J Surg; 2012 May; 36(5):1199-1205. PubMed ID: 22374538
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.
Mathieu LN; Larkins E; Sinha AK; Mishra-Kalyani PS; Jafri S; Kalavar S; Ghosh S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2023 Aug; 29(16):2973-2978. PubMed ID: 36951523
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.
Shukuya T; Takahashi T; Tamiya A; Ono A; Igawa S; Tsuya A; Nakamura Y; Murakami H; Naito T; Kaira K; Endo M; Yamamoto N
Jpn J Clin Oncol; 2009 Mar; 39(3):158-62. PubMed ID: 19139038
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
[TBL] [Abstract][Full Text] [Related]
13. Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).
Lee SW; Choi EK; Chung WK; Shin KH; Ahn SD; Kim JH; Kim SW; Suh C; Lee JS; Kim WS; Kim DS; Kim DK; Park SI; Sohn KH
Lung Cancer; 2002 Jul; 37(1):65-71. PubMed ID: 12057869
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling study.
Plessala I; Cawston H; Cortes J; Ajjouri R; Le Lay K; Souquet PJ; Chouaid C
Lung Cancer; 2023 Oct; 184():107316. PubMed ID: 37562344
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.
Das M; Ogale S; Jovanoski N; Johnson A; Nguyen C; Bhagwakar J; Lee JS
Immunotherapy; 2023 Jun; 15(8):573-581. PubMed ID: 37021770
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
[TBL] [Abstract][Full Text] [Related]
17. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.
Kappers I; van Sandick JW; Burgers SA; Belderbos JS; van Zandwijk N; Klomp HM
Lung Cancer; 2010 May; 68(2):222-7. PubMed ID: 19664843
[TBL] [Abstract][Full Text] [Related]
18. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
[TBL] [Abstract][Full Text] [Related]
19. Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer.
Naim Younes R; Gross JL; Abrao FG; Rodrigues Pereira J
Minerva Chir; 2013 Apr; 68(2):169-74. PubMed ID: 23612230
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy.
Chen P; Yang Q; Li Y; Jing X; Chen J
Front Oncol; 2022; 12():894656. PubMed ID: 36158650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
